CV · Insider Trading
CapsoVision, Inc. Common Stock
Every open-market purchase and sale reported by CV officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-23 | Ching Hang Shen | 10%+ Owner | J | — | — |
| 2026-09-23 | Eliyahou Et Al Harari | 10%+ Owner | Buy | +1,757,469 | +$10.00M |
| 2026-09-23 | Ching Hang Shen | 10%+ Owner | Buy | +878,734 | +$5.00M |
| 2026-09-18 | Ching Hang Shen | 10%+ Owner | Buy | +878,734 | +$5.00M |
| 2026-07-21 | Eliyahou Et Al Harari | 10%+ Owner | Buy | +61,068 | +$410.99K |
| 2026-07-10 | Eliyahou Et Al Harari | 10%+ Owner | Buy | +81,300 | +$495.12K |
| 2026-07-07 | Eliyahou Et Al Harari | 10%+ Owner | Buy | +13,850 | +$101.81K |
| 2026-07-02 | David Stanley Shields | Director | A | +1,710 deriv. | — |
| 2026-07-01 | Joanne Carol Imperial | Director | Sell | −1,200 | −$8.59K |
| 2026-07-01 | Chen Lung Tsai | Director | M | +2,022 | +$15.33K |
| 2026-07-01 | Michele Harari | Director | M | +2,022 | +$15.33K |
| 2026-07-01 | Hui Ying Kuo | Director | M | +2,022 | +$15.33K |
| 2026-07-01 | Joanne Carol Imperial | Director | M | +2,022 | +$15.33K |
| 2026-07-01 | Julia S Gouw | Director | M | +2,022 | +$15.33K |
| 2026-07-01 | Wen-Herng Henry King | Director | M | +2,022 | +$15.33K |
| 2026-06-03 | David Michael Garcia | Sr. VP of Finance | A | +92,212 deriv. | — |
| 2026-06-03 | Kang-Huai Wang | See Remarks | A | +358,344 deriv. | — |
| 2026-06-03 | Douglas Patrick Atkinson | Head of Global Sales | A | +158,078 deriv. | — |
| 2026-05-06 | Douglas Patrick Atkinson | Head of Global Sales | M | +107,357 | +$44.69K |
| 2026-03-23 | Chen Lung Tsai | Director | A | +4,045 deriv. | — |
| 2026-03-23 | Hui Ying Kuo | Director | A | +4,045 deriv. | — |
| 2026-03-23 | Joanne Carol Imperial | Director | A | +4,045 deriv. | — |
| 2026-03-23 | Julia S Gouw | Director | A | +4,045 deriv. | — |
| 2026-03-23 | Wen-Herng Henry King | Director | A | +4,045 deriv. | — |
| 2026-03-23 | Michele Harari | Director | A | +4,045 deriv. | — |
| 2026-02-06 | Chen Lung Tsai | Director | Buy | +20 | +$83 |
| 2025-12-31 | Chen Lung Tsai | Director | M | +2,887 | +$30.86K |
| 2025-12-31 | Joanne Carol Imperial | Director | M | +2,887 | +$30.86K |
| 2025-12-31 | Michele Harari | Director | M | +2,887 | +$30.86K |
| 2025-12-31 | Wen-Herng Henry King | Director | M | +2,887 | +$30.86K |
| 2025-12-31 | Hui Ying Kuo | Director | M | +2,887 | +$30.86K |
| 2025-12-31 | Julia S Gouw | Director | M | +2,887 | +$30.86K |
| 2025-11-03 | David Michael Garcia | Sr. VP of Finance | A | +165,000 deriv. | — |
| 2025-09-17 | Michele Harari | Director | A | — | — |
| 2025-09-17 | Joanne Carol Imperial | Director | A | +2,887 deriv. | — |
| 2025-09-17 | Hui Ying Kuo | Director | A | +2,887 deriv. | — |
| 2025-09-17 | Wen-Herng Henry King | Director | A | +2,887 deriv. | — |
| 2025-09-17 | Chen Lung Tsai | Director | A | +2,887 deriv. | — |
| 2025-09-17 | Julia S Gouw | Director | A | +2,887 deriv. | — |
| 2025-08-22 | Rebecca Ann Petersen | Director of Clinical Affairs | M | +24,834 | +$9.10K |
| 2025-07-08 | Eliyahou Et Al Harari | 10%+ Owner | C | +4,222,422 | — |
| 2025-07-08 | Eliyahou Et Al Harari | 10%+ Owner | C | +4,222,422 | — |
| 2025-07-07 | Kang-Huai Wang | See Remarks | C | +446,896 | — |
| 2025-07-07 | Wen-Herng Henry King | Director | C | +20,710 | — |
| 2025-07-07 | Chen Lung Tsai | Director | C | +91,432 | — |
| 2025-07-07 | Hui Ying Kuo | Director | C | +10,354 | — |
| 2012-06-28 | William J Deehan | — | D | −21,116 | — |
| 2012-06-28 | Dale A Rocheleau | — | MIXED | −6,410 | +$409.04K |
| 2012-06-28 | Joseph M Kraus | — | D | −28,585 | — |
| 2012-06-28 | William R Sayre | — | D | −5,926 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Ching Hang Shen | 10%+ Owner | 7,279,261 | $49.72M |
| Eliyahou Et Al Harari | 10%+ Owner | 1,396,494 | $9.54M |
| Kang-Huai Wang | See Remarks | 721,732 | $4.93M |
| Chen Lung Tsai | Director | 120,385 | $822.23K |
| Douglas Patrick Atkinson | Head of Global Sales | 107,357 | $733.25K |
| Michele Harari | Director | 61,065 | $417.07K |
| Wen-Herng Henry King | Director | 25,619 | $174.98K |
| Rebecca Ann Petersen | Director of Clinical Affairs | 24,834 | $169.62K |
| Hui Ying Kuo | Director | 15,263 | $104.25K |
| Julia S Gouw | Director | 4,909 | $33.53K |
| Joanne Carol Imperial | Director | 3,709 | $25.33K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CV quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.